Obagi Medical unveils ALOHA Program to launch saypha MagIQ

Obagi Medical announced the launch of the Aesthetic Leadership with Obagi Hyaluronic Acid Program. This structured clinical collaboration initiative accelerates aesthetic innovation through practice-led insights and will support the introduction of Obagi saypha MagIQ- the company’s first FDA-approved injectable hyaluronic acid filler. The ALOHA program creates a platform for practices to integrate real-world clinical experience into the product lifecycle. Participants will incorporate Obagi saypha MagIQ into routine treatments and provide structured feedback via standardized surveys from injectors and practice owners. This authentic, practice-driven approach captures insights beyond pivotal trials, informing post-launch education, scientific content, and wider adoption.